<DOC>
	<DOCNO>NCT02034071</DOCNO>
	<brief_summary>• This single-center , open-label , single-arm study double-blind , placebo-controlled , randomized withdrawal extension . Patients initiated DCCR dose 1.5 mg/kg ( maximum start dose 145 mg ) titrate every 14 day 2.4 mg/kg , 3.3 mg/kg , 4.2 mg/kg , 5.1 mg/kg ( maximum dose 507.5 mg ) . These DCCR dos equivalent diazoxide dose 1.03 , 1.66 , 2.28 , 2.9 , 3.52 mg/kg . The administer dose close mg/kg dose achieve available dose strength DCCR . Patients up-titrated visit discretion investigator . All patient continue double-blind , placebo-controlled , randomized withdrawal extension . Any patient show increase rest energy expenditure and/or reduction hyperphagia Baseline Day 55 Day 69 designate responder , whereas others designate non-responders . Responders randomize 1:1 ratio either continue active treatment dose treat Day 69 placebo equivalent dose additional 4 week . Non-responders continue open label treatment extension .</brief_summary>
	<brief_title>Clinical Study Diazoxide Choline Controlled-Release Tablet ( DCCR ) Patients With Prader-Willi Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Prader-Willi Syndrome</mesh_term>
	<mesh_term>Choline</mesh_term>
	<mesh_term>Diazoxide</mesh_term>
	<criteria>Children . adolescent young adult genetically confirm PraderWilli syndrome Ages ≥ 10 year ≤ 22 year Generally healthy document medical history , physical examination , vital sign assessment , 12lead electrocardiogram ( ECG ) , clinical laboratory assessment BMI exceed 95th percentile age specific BMI value CDC BMI chart Fasting glucose ≤ 126 mg/dL HbA1c ≤ 6.5 % Administration investigational drug within 1 month prior Screening Visit Anticipated requirement use prohibit medication History allergic reaction significant intolerance : diazoxide , thiazide sulfonamides Anticipate transition care family home group home similar potentially disruptive change Congestive heart failure know compromised cardiac reserve Any clinically significant endocrine , cardiovascular , pulmonary , neurological , psychiatric , hepatic , gastrointestinal , hematological , renal , dermatological disease interfere assessment investigational drug , accord Investigator</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>22 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Prader-Willi syndrome</keyword>
</DOC>